Status:
COMPLETED
Effect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
This trial is conducted in Asia. The trial is designed to compare the effect on glycaemic control of liraglutide or glimepiride added to metformin in subjects with type 2 diabetes
Eligibility Criteria
Inclusion
- Type 2 diabetes
- Subjects diagnosed with type 2 diabetes and treated with one or more oral antidiabetic drugs (OADs) for the last 3 months
- HbA1c: 7.0-11.0% (both incl.) for subjects on OAD alone
- HbA1c: 7.0-10.0 % (both incl.) for subjects on OAD combination therapy
- BMI less than 45.0 kg/m\^2
Exclusion
- Treatment with insulin within the last 3 months prior to the trial
- Impaired liver or/and renal function
- Significant cardiovascular disease over the last 6 months
- Known retinopathy or maculopathy
- Recurrent major hypoglycaemia or hypoglycaemic unawareness
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2009
Estimated Enrollment :
929 Patients enrolled
Trial Details
Trial ID
NCT00614120
Start Date
January 1 2008
End Date
February 1 2009
Last Update
March 8 2017
Active Locations (50)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Beijing, Beijing Municipality, China, 100029
2
Novo Nordisk Investigational Site
Beijing, Beijing Municipality, China, 100730
3
Novo Nordisk Investigational Site
Chongqing, Chongqing Municipality, China, 400010
4
Novo Nordisk Investigational Site
Fuzhou, Fujian, China, 350025